Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies.

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...